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Abstract Objective: To design clear guidelines for the
staging and follow-up of patients with uterine cervical
cancer, and to provide the radiologist with a framework for
use in multidisciplinary conferences. Methods: Guidelines
for uterine cervical cancer staging and follow-up were
defined by the female imaging subcommittee of the ESUR
(European Society of Urogenital Radiology) based on the
expert consensus of imaging protocols of 11 leading
institutions and a critical review of the literature. Results:
The results indicated that high field Magnetic Resonance
Imaging (MRI) should include at least two T2-weighted
sequences in sagittal, axial oblique or coronal oblique
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orientation (short and long axis of the uterine cervix) of the
pelvic content. Axial T1-weighted sequence is useful to
detect suspicious pelvic and abdominal lymph nodes, and
images from symphysis to the left renal vein are required.
The intravenous administration of Gadolinium-chelates is
optional but is often required for small lesions (<2 cm) and
for follow-up after treatment. Diffusion-weighted sequences
are optional but are recommended to help evaluate lymph
nodes and to detect a residual lesion after chemoradiother-
apy. Conclusions: Expert consensus and literature review
lead to an optimized MRI protocol to stage uterine cervical
cancer. MRI is the imaging modality of choice for
preoperative staging and follow-up in patients with uterine
cervical cancer.
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Introduction
Uterine cervical cancer is the third most common gynaeco-
logical malignancy after endometrial and ovarian cancers [1].
Nearly 80% of cervical cancer occurs in the developing
countries and most patients are diagnosed with the disease at
an advanced stage, thus not suitable for surgical staging.
Therefore cervical cancer usually remains a clinically staged
disease [2]. However, there are significant inaccuracies in the
clinical staging system compared to surgical staging, with an
error rate up to 32% in patients with stage IB disease and up
to 65% of patients with stage III disease [3]. The greatest
difficulties in the clinical examination of patients with
cervical cancer are accurate estimation of tumour size, the
assessment of parametrial and pelvic side wall invasion, and
the evaluation of lymph node metastases which are recog-
nized important prognostic factors [4]. Despite these inherent
limitations of the clinical examination, uterine cervical
cancer is the only gynaecological cancer still largely staged
clinically, in accordance with the classification of the
International Federation of Gynaecology and Obstetrics
(FIGO).
In June 2009 the FIGO committee introduced the revised
staging [5] of cervical carcinoma updating the previous
staging of 1988 (Tables 1 and 2). Although the revised FIGO
staging system does not include imaging in the staging of
cervical cancer, for the first time the committee encourages
the use of imaging techniques, if available, to assess the
important prognostic factors such as tumour size, parametrial
and pelvic side wall invasion, adjacent organ invasion and
the evaluation of lymph node metastases. Imaging is thus
complementary to the clinical assessment with MRI being
the optimal modality to stage cervical carcinoma FIGO stage
1B1 or greater. Furthermore, in young patients with small
invasive tumours and who desire to preserve fertility a more
conservative surgical procedure (trachelectomy) can be
performed. In these cases MRI staging is mandatory in order
to determine eligibility in terms of tumour size (<2 cm),
cervical length (>2.5 cm) and distance from the tumour to
Table 1 New FIGO classification for cervical carcinoma. FIGO COMMITTEE ON GYNECOLOGIC ONCOLOGY International Journal of
Gynecology and Obstetrics 105 (2009) 103–104
Stage I: The carcinoma is strictly confined to the cervix (extension to the corpus would be disregarded)
IA Invasive carcinoma which can be diagnosed only by microscopy, with deepest invasion≤5 mm and largest extension≥7 mm
IA1 Measured stromal invasion of≤3.0 mm in depth and extension of≤7.0 mm
IA2 Measured stromal invasion of N3.0 mm and not N5.0 mm with an extension of not N7.0 mm
IB Clinically visible lesions limited to the cervix uteri or pre-clinical cancers greater than stage IA ⁎
IB1 Clinically visible lesion≤4.0 cm in greatest dimension
IB2 Clinically visible lesion N4.0 cm in greatest dimension
Stage II: Cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina
IIA Without parametrial invasion
IIA1 Clinically visible lesion≤4.0 cm in greatest dimension
IIA2 Clinically visible lesion N4 cm in greatest dimension
IIB With obvious parametrial invasion
Stage III: The tumour extends to the pelvic wall and/or involves lower third of the vagina and/or causes hydronephrosis or non-functioning kidney
IIIA Tumour involves lower third of the vagina, with no extension to the pelvic wall
IIIB Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney
Stage IV: The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. A bullous
edema, as such, does not permit a case to be allotted to Stage IV
IVA Spread of the growth to adjacent organs
IVB Spread to distant organs
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the internal cervical os (>1 cm). In order to achieve maximal
staging accuracy by means of MRI, it is essential to ensure
adequate patient preparation, optimal imaging sequences and
adequate reporting expertise. Therefore, the female pelvis
subcommittee of the European Society of Urogenital
Radiology (ESUR) formed a working group to establish
technical guidelines for uterine cervical cancer staging with
MRI based on extended clinical practice.
Material and methods
MRI protocols for staging of cervical cancer were collected
from eleven European Institutions. Inclusion criteria to
participate in the guideline process were: to be a member of
the European Society of Urogenital Radiology (ESUR) and to
perform at least ten MRI examinations per year for staging
biopsy-proven cervical carcinoma. Members of the ESUR are
experts in gynaecological imaging, especially in pelvic MRI.
The questionnaire contained the following information: patient
preparation, magnet field strength, type of coil, type of
sequence with detailed geometry and contrast information,
such as FOV, matrix scan and reconstruction, slice thickness,
gap, orientation, saturation bands, 2D versus 3D sequence, TR/
TE, use of number of acquisitions, number and lengths of
dynamic sequences, use of bolus intravenous (IV) injection and
subtraction techniques and use of diffusion weighted imaging
(DWI) sequences. In addition, published literature between
1999 and 2010 was reviewed through a Medline literature
search of abstracts in the English language of studies in human
subjects, including the following key words: “Uterine neo-
plasm(s) AND MR imaging” and “Uterine cervical carcinoma
AND MR imaging.” Articles that did not include technical
details matching the information requested in the questionnaire
were excluded. The details were entered in an excel sheet and
the results were discussed and divided in topics with agreement
and disagreement. Topics with disagreement were compared to
the literature. Experts in favour of one technical option were
asked to support their views using data from the literature.
These were subsequently discussed by an expert panel. The
collected data from the ESUR member institution was
compared to the data from the literature which took into
consideration year of publication, number of cases and
performance of the technique. When technical details varied
and no published work on performance was found, the subject
was discussed and resolved in consensus based on the majority
of participating members. Members of the group met twice a
year during a 2-year period and were asked to apply technical
recommendations issued after the first two meetings during the
year before the meetings in year 2 in order to allow further
discussion and the issue of final recommendations in consen-
sus. Validation of the manuscript has been done collegially with
the agreement of the ESUR committee.
Results
Indications for MRI in uterine cervical cancer
All the eleven ESUR members recommend MRI for staging
of tumours stage 1B1 and over or smaller tumours if
trachelectomy is being considered. They also all recom-
mended MRI for treatment follow-up (after brachytherapy
and chemoradiation therapy) and detection of tumour
recurrence. There was no consensus among 11 ESUR
participants regarding the MRI time-delay after treatment.
This varied from 3 weeks to 6 months with the majority
recommending MRI 3–6 months after completion of
chemoradiation therapy and brachytherapy. Similarly, there
was no consensus on the frequency of follow-up. Some
ESUR members perform yearly follow-up MRI for 5 years
and some only if there are symptoms of recurrence. Three
members use PET/CT routinely as complementary to MRI
staging, 5 only if there are indeterminate lymph nodes on
MRI and 2 only before salvage therapy.
Technical requirements for MRI in uterine cervical cancer
Among the eleven ESUR members, 6 worked with a 1.5 T
magnet, 1 with a 3.0 T magnet and 4 members with both 1.5
and 3.0 T magnet, Most of the published studies in the
literature use a 1.5 T magnet. There are only a few published
Table 2 Proposed protocol for MRI in cervical cancer staging and evaluation
• Optional use of fasting, Antiperistaltic IV injection, or vaginal/rectal sonographic gel opacification
• Axial T2w sequence, without a fat suppression : pelvis and abdomen (renal hilum) : 5 mm / 0.5 (pelvis), 6 mm / 1 mm (abdomen) ; matrix>
400×400
• Sagittal T2w sequence without a fat suppression : pelvis 5 mm / 0.5 (pelvis) ; matrix>400×400
• Coronal oblique T2w perpendicular to the cervix, thin slices (4 mm/0.4 mm) ; matrix>400×400
• Optional: in case of small lesions, not well depicted on T2w images, and after treatment.
◦ Sagittal 3D T1w dynamic sequences after gadolinium chelates injection : one native and 4 post contrast (total 5 scans with a total acquisition
time of about 5 mn)
◦ DWI sequences
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studies using a 3 T MRI, showing very promising results in
cervical cancer [6]. At 3 T, spatial resolution is improved,
allowing accurate local staging and detection of a residual
tumour after treatment [6]. At 3.0-T imaging, mean tumour
signal-to-noise ratios, mean cervical stroma signal-to-noise
ratios, and mean tumour-to-cervical stroma contrast-to-noise
ratios are higher than those at 1.5-T imaging. Nevertheless,
image homogeneity at 3.0-T imaging seems inferior to that at
1.5-T imaging. In recent published studies, even if imaging
quality seems to be higher at 3 T, accuracy seems to be
equivalent at 1.5 T and 3 T (6).
a. Patient Preparation
There was no consensus among the 11 ESUR members or
in the literature regarding the type of preparation before pelvic
MRI. Nevertheless, different types of patient preparations
have been suggested in order to improve the quality of the
examination. Several authors proposed a 6 h fast before MRI
[7, 8] others an IV or intramuscular (IM) injection of
antiperistaltic agent [9] or vaginal/rectal opacification with
sterile gel [10]. The use of an antiperistaltic agent seems to
be the most efficient way to limit bowel motion artifacts. An
intramuscular injection of an antiperistaltic agent is used (1
mg glucagon; (Glucagen ®, Novo Nordisk ® ; Bagsværd ;
Denmark) or 20 mg butyl-scopolamine (Buscopan ® ;
Boehringer Ingelheim GmbH ; Ingelheim, Germany) unless
contraindicated (e.g., diabetes or pheochromocytoma) to
decrease peristalsis artifacts. In the ESUR group, only 50%
of the experts included combined fasting and antiperistaltic
agents in their patient preparation protocol. Seven ESUR
centres use an antiperistaltic agent routinely before MRI
examination (4 use IV injection and 3 use IM injection)
whereas four centres do not use an antiperistaltic agent.
Bladder must be half filled in order to improve lesion
visibility without changing anatomy. Vaginal opacification
with gel yielding high signal intensity on T2 weighting may
be useful in case of suspicion of tumour extension into the
vagina in order to differentiate FIGO IIA from FIGO IB
tumour, particularly in the posterior vaginal fornix [10];
however only one ESUR centre uses a vaginal opacification
routinely and two others only if there is a suspicion of
posterior fornix invasion at physical examination. Therefore,
the use of intraluminal (vagina/rectum) contrast agents
before the MRI staging of uterine cervical carcinoma
remains optional.
b. Use of Intravenous Contrast Medium
There is wide variation among the 11 ESUR members and
in the literature regarding the use of IV contrast medium for
cervical cancer staging. Seven of the 11 ESUR members use
IV contrast medium routinely for staging of cervical cancer
and identification of small tumours, one uses it only for
detection of tumour recurrence and three do not use IV)
contrast medium. Among those 7 centres that use IV contrast
medium, 6 use a dynamic acquisition and 1 uses a semi-
dynamic one. The results of the literature are also variable
with some authors using IV contrast medium systematically in
all cases [10–12] whereas other authors not using IV contrast
medium at all [13, 14]. In a dynamic acquisition, contrast
enhancement of the tumour is lower than the myometrium in
the early phase, whereas on the late phases, tumour signal
intensity is higher than the myometrium. Thus, interpretation
of images is easier on the earlier phases of contrast medium
enhancement. The use of IV contrast medium increases the
contrast between the tumour and normal cervical stroma and
can improve tumour detection and localization, this is
especially useful for small tumours which may be considered
for trachelectomy [15]. Van Vierzen et al [15] found that the
combination of pre-contrast and post-contrast MR images
did not clearly improve staging accuracy (83%). However,
the addition of fast dynamic contrast-enhanced MRI im-
proved staging accuracy to 91%. The use of dynamic
contrast-enhanced MRI also improves the accuracy of
assessment of bladder and rectal wall invasion [15].
Furthermore, the use of IV contrast medium is useful in the
post-treatment setting to differentiate residual or recurrent
tumour from radiation fibrosis [16] as well as presence of
fistulae occurring post radiation therapy.
c. Imaging Sequences
There is significant variability in the literature regarding the
MRI protocols used. The number of the sequences can vary
from 3 [17] to more than 5 [18]. There was a consensus in
the ESUR group that the essential protocol must include a
combination of at least two T2-weighted sequences obtained
in the sagittal and oblique (perpendicular to the cervical
canal) planes and T1W sequences of the upper abdomen and
pelvis. Lymph node evaluation might be done also on T2
sequences in an axial plan, from pelvis to left renal vein.
T2w sequences are the best sequences to detect the
cervical tumour and its extension to the uterus, parametria
and the adjacent organs [19] (Fig. 1). The use of fat
suppression is not recommended as the presence of para-
metrial fat can lead to better tumour delineation. All the
ESUR centres and most of the authors in the literature are
performing T2w sequences in two orthogonal planes such
as sagittal and oblique [19]. Oblique images must be
acquired perpendicularly to the long axis of the cervical
canal. Slice thickness varied from 3 to 6 mm, with a 0.25
gap. For optimal image quality, T2-weighted images
covering the pelvis should be acquired with a small FOV
(20–25 cm) and ideally with a 512×512 matrix. 8 of 18
reviewed papers also add a coronal T2w sequence on the
pelvis with thin slices (3-4 mm/0.4 mm) to assess para-
metrial extension [20] (Fig. 2). All the ESUR centres and
several authors in the literature are also obtaining images of
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the abdomen (from the level of the renal veins to the pelvic
brim) to evaluate for presence of abnormal lymph nodes [7,
19, 21] (Fig. 3). Both T1 and T2—weighted images can be
used for this purpose. This obviates the need for an
additional CT of the abdomen. The total acquisition time
for the entire staging MRI is 25–30 min.
T1w sequences were part of the MRI staging protocol
with 14/18 reviewed papers and nearly all members of the
ESUR group performing T1w images without fat suppres-
sion. T1w sequences are very useful to evaluate for
presence of lymphadenopathy, bone metastases and also
in the rare occasion of hematometria. Therefore, they
should be mandatory. Nevertheless, lymph node evaluation
can also be done accurately on T2w axial sequences.
Diffusion weighted imaging (DWI) Although there is little
published data, DWI seems to be a very promising
emerging technique in the evaluation of uterine cervical
cancer [8, 22–25]. Seven ESUR centres routinely use DWI.
Cervical carcinoma has a lower apparent diffusion coeffi-
cient (ADC) compared to the normal cervix (Fig. 4). The
ADC increases after chemoradiotherapy [26]. There is a
variability in the B-values used with a range of B values
between 500 and 1000bms/-2 [26, 27]. DWI may be helpful
in detection of residual tumour or suspicious lymph nodes
after chemoradiotherapy [8], and might be competitive with
PET-imaging [28, 29]. A recent paper showed that the pre-
treatment ADCs of patients with complete response are
lower than that of those with partial response, and pre-
treatment ADC values of all patients correlated negatively
with the percentage size reduction of the tumour after 2
months of chemoradiation. A possible explanation for this
observation is that tumours with high pretreatment ADC
values are likely to be more necrotic than those with low
Fig. 1 Sagittal T2w image,MRI. 45 years old woman, stage IB2 cervical
carcinoma. T2W images demonstrate the tumour (arrow) invading the
cervical stroma. Vaginal opacification with gel yielding high signal
intensity on T2 weighting does not depict any vaginal invasion
Fig. 2 Sagittal and axial T2W
images, MRI. 38 years old
woman, stage IB2 cervical
carcinoma. Hyperintense lesion
is invading the cervical stroma
(Fig 2a). Coronal oblique
section shows an intact low
signal intensity cervical stroma
(arrows, Fig 2b) accurately
excluding presence of
parametrial invasion
Fig. 3 Axial T2W image, MRI. 47 years old woman, stage IIB cervical
carcinoma. Lymph node spreading. An abnormal lymph node (small axis>
10mm) is seen in the para-aortic space (arrow). It is mandatory to perform
in the same examination a pelvic and an abdominal staging, with slices
from the symphysis to the left renal vein
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ADC values [8]. We recommend performing optional DWI
sequences of the pelvis and the abdomen.
Reporting
The following check list is helpful for a comprehensive and
easy to read report.
a. Description of the lesions
Cervical tumour is depicted on T2w images as a
hyperintense mass compared to the cervical stroma [30,
31]. Tumour size (in three dimensions) must be evaluated
in at least two orthogonal views; it is crucial to give
precise measurements as size of the tumour can dictate
treatment options. Fertility sparing surgery is possible
with tumours <2 cm whereas patients with tumours >4 cm
may undergo chemoradiotherapy rather than radical
surgery.
b. Local staging
- Vaginal extension: precise description should be
given if the extension is anterior or posterior. If the
lesion reaches the 2/3 of the upper vagina, it is a
FIGO IIA; if the lesion invades the 1/3 inferior part
of the vagina, it is a FIGO IIIA.
- Parametrial extension: stromal invasion is present
if there is a disruption of the hypointense line
circumscribing the cervix on oblique T2w images
(Fig. 5). Parametrial invasion is present if in
addition to the stromal invasion there is tumour
present in the parametrium, a spiculated tumour-
parametrial interface or tumour encasement of the
peri-uterine vessels [12]. Presence of hydroneph-
rosis is consistent with parametrial invasion.
Accuracy of MRI in assessing parametrial invasion
varies from 80 to 87% according to the literature
[32].
Fig. 4 Sagittal and axial T2W images, MRI; DWI images with ADC
map (B 800). 42 years old woman, stage IIB cervical carcinoma. A
2 cm hyperintense lesion is seen in the cervix (arrow) (Fig 4a) with
right parametrial invasion (Fig 4c) (arrowheads) and a beginning of
left parametrial invasion (arrow). Sagittal and axial DWI images
(Fig 4b) and Fig 4d show high signal intensity on DWI and with a low
signal intensity on the ADC map (Fig 4e) suggesting restricted
diffusion
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- Isthmic extension: clinical evaluation is not
accurate in case of isthmic invasion. The reporting
should include it because positioning of brachy-
therapy coils might be dependant of the level of
isthmic tumour extension [33].
c. Lymph node staging
FIGO classification does not include the nodal status.
Yet, lymph node spreading is one of the most important
prognostic factors in cervical carcinoma [34, 35]. Accuracy
of MRI is low for lymph node staging, with a sensitivity
varying from 38 to 89%, and a specificity from 78 to 99%
[36, 37]. Due to its high sensitivity, PET-CT is recom-
mended for locally advanced cervical carcinoma with no
abnormal lymph node depicted in the pelvis or the abdomen
[38]. Size criterion for a suspicious lymph node is a short
axis superior to 1 cm, in the pelvis or the abdomen [39].
However, smaller lymph nodes may be malignant, espe-
cially in the pelvis; therefore it is important to take in
account other features of malignancy such as round shape,
irregular margins, signal intensity similar to the primary
tumour and presence of necrosis.
d. Evaluation of Tumour Response to Treatment
Chemoradiotherapy followed by brachytherapy is the
standard treatment for patients with locally advanced
uterine cervical carcinoma (> IB1 FIGO stage) [40].
Surgery is usually avoided in case of complete response
following chemoradiotherapy treatment, due to its high rate
of urinary side effects (incontinence, uteral distension,
chronic bladder infection …). Tumour response evaluation
is based on three criteria: clinical examination, PAP smear
analysis and post treatment MR evaluation [41].
After treatment, MR protocol is the same as for cervical
cancer staging, but IV injection is recommended. MR
criteria for a complete response include:
– no lesion seen in the cervix or in the adjacent anatomic
areas
– homogeneous hypointense cervical stroma
– homogeneous and delayed intravenous contrast medi-
um uptake of the cervix after IV injection [42] (Fig. 6).
Interpretation and performance of MRI in the follow-up
setting are lower compared to the primary staging tumour
detection. It is useful to compare the post treatment images
with the pre-treatment images to facilitate tumour detection
and re-staging.
e. Detection of a recurrence
- After medical treatment:
There is no consensus among the ESUR centres on in the
reviewed literature regarding the indication of MRI for the
follow-up of patients with treated cervical carcinoma.
Fig. 6 Sagittal T2W image
before a and after b
radiation-chemotherapy (RCT)
and brachytherapy. 37 years old
woman, stage IIB cervical
carcinoma. A 5 cm lesion
invading the cervical stroma is
seen with a hyperintense signal
intensity (arrow, fig a). After
treatment (3 weeks delay), the
tumour is not seen. There is
reconstitution of the normal low
signal intensity cervical stroma
suggestive of complete response
to treatment. No residual tumour
was found at hysterectomy
Fig. 5 Axial T2W image, MRI. 49 years old woman, stage IIB cervical
carcinoma. Parametrial tumoural extension is seen on both sides of
uterine cervix (arrows). Limits of cervical stroma are nearly not visible
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Usually, MRI is performed when there is a clinical
suspicion of recurrence.
– After surgery :
There is also no consensus for a systematic MR follow-
up. Nevertheless, in case of trachelectomy, an MRI at 6
months and 1 year is advised, because recurrence rate is
higher compare to patients who undergo brachytherapy or
chemotherapy [43].
Conclusion
Although FIGO staging system does not include imaging in
the staging of cervical cancer, in the revised FIGO system
imaging techniques are encouraged to assess the important
prognostic factors and imaging is now complimentary to
the clinical assessment. Radiologists must familiarize
themselves with the new FIGO staging system and
understand its relevance to patient management. Magnetic
resonance imaging is the imaging modality of choice for
staging the primary cervical tumour, evaluate response to
treatment and detect tumour recurrence and potential
complications. Adequate patient preparation, protocol opti-
mization and MRI reporting expertise are essential to
achieve high diagnostic accuracy.
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